Skip to content

Journal of Clinical Psychopharmacology

ISSN 0271-0749, 1533-712X

66 papers in the library · 2,233 citations · publishing 0-2026

Papers

Sort Most recent Most cited

Effects of Repeated Intravenous Ketamine in Treatment-Resistant Geriatric Depression

Journal of Clinical Psychopharmacology March 1, 2019 Kelly A. Bryant, Murat Altinay, Nora Finnegan et al.

Abstract Purpose There is an immediate need for more sustainable, effective therapies for treatment-resistant depression in patients who do not respond to traditional psychopharmacology. The aim of this study was to determine the efficacy and safety of intravenous ketamine infusions on the elderly population by using a case series of 6 geriatric patients with treatment-resistant depression....

Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence.

Journal of Clinical Psychopharmacology December 1, 2018 Thomas Knuijver, Maarten Belgers, Wiebren Markus et al.

expressed in brain regions associated with emotional processing. Modulation of the hypothalamic-pituitary-adrenal axis by altering cortisol tone also seems to be involved in this effect. The ECS modulates stress and anxiety. Serum AEA and 2-AG levels are increased after stress, and AEA levels are negatively associated to baseline anxiety and are significantly reduced in womenwith major...

Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.

Journal of Clinical Psychopharmacology December 2018 Sonia Vidal, Marianne Gex-Fabry, Victor Bancila et al.

Ketamine has been documented for its rapid antidepressant effects. However, optimal dose and delivery route have not yet been thoroughly investigated. The objectives of this study were to document the safety and test the antidepressant and antisuicidal effects of a single rapid 1-minute injection of ketamine 0.5 mg/kg in treatment-resistant depression (TRD). Ten patients with TRD were included...

Possible Interactions Between 5-HT2A Receptors and the Endocannabinoid System in Humans

Journal of Clinical Psychopharmacology October 19, 2018 Rafael G. Dos Santos, José Alexandre S. Crippa, Flávia de Lima Osório et al. 9 citations

dos Santos, Rafael Guimarães PhD; Crippa, José Alexandre MD, PhD; Osório, Flávia de Lima PhD; Rocha, Juliana M. BSc; Rossi, Giordano Novak BSc; Marchioni, Camila BSc; Queiroz, Maria Eugênia Costa PhD; Silveira, Gabriela O. BSc; Yonamine, Mauricio PhD; Hallak, Jaime Eduardo Cecilio MD, PhD Author Information

Methylenedioxymethamphetamine (MDMA) in Psychiatry

Journal of Clinical Psychopharmacology October 10, 2018 Susan Schenk, David Newcombe 53 citations

Abstract Background For a number of mental health disorders, including posttraumatic stress disorders (PTSD), there are not many available treatment options. Recently, there has been renewed interest in the potential of methylenedioxymethamphetamine (MDMA) to restore function for patients with these disorders. The primary hypothesis is that MDMA, via prosocial effects, increases the ability of...

Ineffectiveness of Repeated Intravenous Ketamine Infusions in Treatment-Resistant Depression After a Post-Ketamine Relapse: Time for a Rethink?

Journal of Clinical Psychopharmacology October 1, 2018 Á. López-Díaz, J. L. Fernández-González

To the Editors: W orldwide, major depressive disorder (MDD) is a leading cause of disability and a major contributor to the overall global burden of disease. Up to 30%of patients with MDD have a lack of response to antidepressant therapies. These rates are even higher in bipolar depression, where treatment options are more limited than in MDD. Patients who do not achieve an adequate...

Maintenance Ketamine Therapy for Treatment-Resistant Depression

Journal of Clinical Psychopharmacology August 1, 2018 Shaina Archer, Carson Chrenek, Jennifer Swainson

Abstract Background Previous studies have demonstrated ketamine to have a rapid antidepressant effect in some patients with treatment-resistant depression (TRD), but the effect is unfortunately not sustained in the long term. In this study, we report on the clinical use of ongoing maintenance ketamine infusions in a group of patients with TRD, beyond an acute course of 6 to 8 ketamine...

Exploring Nitrous Oxide as Treatment of Mood Disorders: Basic Concepts.

Journal of Clinical Psychopharmacology April 1, 2018 Peter Nagele, Charles F Zorumski, Charles R Conway

Nitrous oxide (laughing gas) has shown early promise as a rapidly acting antidepressant in patients with treatment-resistant major depression and is currently investigated in several clinical trials. Because nitrous oxide is rarely administered outside operating rooms or dental practices, most psychiatrists are not familiar with how nitrous oxide is administered in a medical setting and what...

Oral Ketamine in Treatment-Resistant Depression: A Clinical Effectiveness Case Series.

Journal of Clinical Psychopharmacology August 2017 Maryam I Al Shirawi, Sidney H. Kennedy, Keith T. Ho et al.

The aim of the study was to assess the effectiveness, tolerability, and safety of oral ketamine as an antidepressant treatment in adults with treatment-resistant depression. We reviewed retrospective data on 22 patients with treatment-resistant depression, who failed at least 3 adequate antidepressant treatment trials and 1 adequate trial of repetitive transcranial magnetic stimulation;...

Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment Refractory Obsessive-Compulsive Disorder

Journal of Clinical Psychopharmacology April 1, 2017 Thomas G. Adams, M. Bloch, Christopher Pittenger

To the Editors: R efractory obsessive-compulsive disorder (OCD) is a common and vexing clinical problem. Agents that modulate glutamate, including theN-methyl-Daspartate antagonist ketamine, have been the focus of recent interest for the treatment of this population, but experience to date has been mixed. Ketamine is a rapid-acting antidepressant that enhances cellular mechanisms associated...

Targeting the Endocannabinoid System in Psychiatric Illness.

Journal of Clinical Psychopharmacology December 2016 Martin A Katzman, Melissa Furtado, Leena Anand

Prevalence of psychiatric disorders continues to rise globally, yet remission rates and patient outcome remain less than ideal. As a result, novel treatment approaches for these disorders are necessary to decrease societal economic burden, as well as increase individual functioning. The recent discovery of the endocannabinoid system has provided an outlet for further research into its role in...

A New Perspective on the Anti-Suicide Effects With Ketamine Treatment

Journal of Clinical Psychopharmacology December 12, 2015 Yena Lee, Kahlood Syeda, Nadia A. Maruschak et al. 75 citations

Available evidence indicates that a single, low-dose administration of ketamine is a robust, rapid-onset intervention capable of mitigating depressive symptoms in adults with treatment-resistant mood disorders. Additional evidence also suggests that ketamine may offer antisuicide effects. Herein, we propose that the antidepressant effects reported with ketamine administration are mediated, in...

Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression

Journal of Clinical Psychopharmacology December 11, 2015 Rafael Faria Sanches, Flávia de Lima Osório, Rafael G. Dos Santos et al. 468 citations

Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in...

Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation.

Journal of Clinical Psychopharmacology October 2014 Colin Cameron, Diane Watson, Jeffrey D. Robinson

Nabilone is a synthetic cannabinoid that has shown promise for the treatment of posttraumatic stress disorder (PTSD)-related insomnia and nightmares as well as efficacy in the management of chronic pain. It has also been proposed for harm reduction in cannabis dependence. Its effectiveness for management of concurrent disorders in seriously mentally ill correctional populations has not been...

α1-Adrenergic Receptors Contribute to the Acute Effects of 3,4-Methylenedioxymethamphetamine in Humans

Journal of Clinical Psychopharmacology July 13, 2013 Cédric M. Hysek, Anja E. Fink, Linda D. Simmler et al. 57 citations

Preclinical studies implicate a role for α₁-noradrenergic receptors in the effects of psychostimulants, including 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). The present study evaluated the effects of the α₁-noradrenergic receptor antagonist doxazosin on the acute pharmacodynamic and pharmacokinetic response to MDMA in 16 healthy subjects. Doxazosin (8 mg/d) or placebo was administered...

Suspected and Confirmed Fatalities Associated With Mephedrone (4-Methylmethcathinone, “Meow Meow”) in the United Kingdom

Journal of Clinical Psychopharmacology August 25, 2012 Fabrizio Schifano, John Corkery, A. Hamid Ghodse 113 citations

BACKGROUND: International media have been reporting about fatalities allegedly related to mephedrone, a popular recreational stimulant, but now a proportion of them have been confirmed. We aimed here at analyzing information relating to the circumstances of mephedrone-related deaths in the United Kingdom. METHODS: Descriptive analysis of information was mainly extracted from the UK National...

DOI: 10.1097/jcp.0b013e318266c70c (opens in new tab) Ecstasy Mephedrone Recreational drug Stimulant +4

A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder

Journal of Clinical Psychopharmacology June 20, 2012 Lobna Ibrahim, Nancy Diazgranados, Libby Jolkovsky et al. 219 citations

Converging lines of evidence suggest that the glutamatergic system may play an increasingly important role in the development of novel therapeutics for major depressive disorder (MDD), particularly agents associated with rapid antidepressant effects. Diverse glutamatergic modulators targeting N-methyl-D-aspartate receptors have shown efficacy in MDD, but their associated psychotomimetic effects...

Using Ketamine to Model Semantic Deficits in Schizophrenia

Journal of Clinical Psychopharmacology October 21, 2011 Erica Neill, Susan Lee Rossell, Sarah McDonald et al. 11 citations

Semantic deficits constitute a core cognitive abnormality in schizophrenia. In the current study, the N-methyl-d-aspartate receptor antagonist ketamine was administered to healthy individuals acutely while they performed semantic processing tasks that included word pairs of differing degrees of semantic relatedness. Two dimensions of semantic processing were investigated: (1) explicit versus...

Autonomic, Neuroendocrine, and Immunological Effects of Ayahuasca

Journal of Clinical Psychopharmacology October 15, 2011 Rafael G. Dos Santos, Marta Valle, José Carlos Bouso et al. 136 citations

Ayahuasca is an Amazonian psychotropic plant tea combining the 5-HT2A agonist N,N-dimethyltryptamine (DMT) and monoamine oxidase-inhibiting β-carboline alkaloids that render DMT orally active. The tea, obtained from Banisteriopsis caapi and Psychotria viridis, has traditionally been used for religious, ritual, and medicinal purposes by the indigenous peoples of the region. More recently, the...

DOI: 10.1097/jcp.0b013e31823607f6 (opens in new tab) Ayahuasca Hallucinogen Pharmacology Amphetamine +2

Antagonist-elicited cannabis withdrawal in humans.

Journal of Clinical Psychopharmacology October 2011 David A. Gorelick, Robert S. Goodwin, Eugene Schwilke et al.

Cannabinoid CB1 receptor antagonists have potential therapeutic benefits, but antagonist-elicited cannabis withdrawal has not been reported in humans. Ten male daily cannabis smokers received 8 days of increasingly frequent 20-mg oral Δ⁹-tetrahydrocannabinol (THC) dosages (40-120 mg/d) around-the-clock to standardize cannabis dependence while residing on a closed research unit. On the ninth...

Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia.

Journal of Clinical Psychopharmacology June 2009 Glenn Schwarcz, Basawaraj Karajgi, Richard McCarthy

We are reporting improvement of symptoms of schizophrenia in a small group of patients who received the cannabinoid agonist dronabinol (synthetic Delta-9-tetrahydrocannabinol). Before this report, cannabinoids had usually been associated with worsening of psychotic symptoms. In a heuristic, compassionate use study, we found that 4 of 6 treatment-refractory patients with severe chronic...

The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans

Journal of Clinical Psychopharmacology September 12, 2008 Brian O’Mathúna, Magı́ Farré, Amin Rostami‐hodjegan et al. 68 citations

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a widely abused substituted amphetamine. MDMA is predominantly O-demethylenated in humans by cytochrome P450 isoforms 2D6 and 1A2 (CYP2D6 and CYP CYP1A2, respectively). MDMA is also a mechanism-based inhibitor of CYP2D6. A controlled clinical trial was conducted in 15 healthy male subjects whereby a probe drug, dextromethorphan (DEX), was...

Relative Abuse Liability of γ-Hydroxybutyric Acid, Flunitrazepam, and Ethanol in Club Drug Users

Journal of Clinical Psychopharmacology December 1, 2007 Sergio Abanades, Magı́ Farré, Diego Barral et al. 69 citations

OBJECTIVES: Despite the increasing concern about gamma-hydroxybutyric acid (GHB) toxicity, there are few studies examining the clinical pharmacology of GHB and its abuse potential. To evaluate GHB-induced subjective and physiological effects, its relative abuse liability and its impact on psychomotor performance in club drug users. MATERIALS AND METHODS: Twelve healthy male recreational users...

DOI: 10.1097/jcp.0b013e31815a2542 (opens in new tab) Flunitrazepam Abuse liability Drug Pharmacology +1

Antidepressant Effects of the Herb Salvia Divinorum: A Case Report

Journal of Clinical Psychopharmacology December 1, 2001 Karl R. Hanes 69 citations

Ms. G is a 26-year-old woman with a history of depression that has shown no significant periods of remission since adolescence and has been predominated by feelings of worthlessness, lack of interest in social activities, an absence of occupational satisfaction, and inability to find purpose and meaning in her life. After first seeking treatment for her depression 5 years ago Ms. G was...

DOI: 10.1097/00004714-200112000-00025 (opens in new tab) Antidepressant Traditional medicine Salvia Medicinal herbs